[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100336022":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":43,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":7,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":7,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"PROCEDURE","Lung Tumor Resection",[13],{"name":14,"affiliation":15,"role":16},"Josephine Taverna, MD","UT Health San Antonio M.D. Anderson Cancer Center","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","210-450-8234","tavernaj@uthscsa.edu",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"UT Health San Antonio, M.D. Anderson Cancer Center","RECRUITING","San Antonio","Texas","78229","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-98.49363,29.42412,{"lat":35,"lon":34},[38,42],{"name":39,"role":19,"phone":40,"phoneExt":7,"email":41},"Research Office","210-450-1000","mccresearch@uthscsa.edu",{"name":14,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":16,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Josephine Taverna","Principal Investigator",[47],{"name":48,"class":49},"National Cancer Institute (NCI)","NIH","100336022","patient-derived-organoid-model-and-circulating-tumor-cells-for-treatment-response-of-lung-cancer-100336022",false,"NCT03655015","Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer","Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)","Inclusion Criteria:\n\n* Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.\n* Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care\n* Any clinical stage of lung cancer\n* Adult patients ≥18 years of age\n* Able and willing to complete a questionnaire on their environmental\u002Foccupational exposures and smoking\u002Falcohol history\n\nExclusion Criteria:\n\n* At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.","ALL","18 Years",{"count":60,"type":61},150,"ESTIMATED","OBSERVATIONAL","Create a living biobank of PDOs from Stage I-III lung cancer patients.",[65],"Lung Neoplasm","2026-04-16",{"date":68,"type":69},"2026-04-20","ACTUAL",{"date":71,"type":69},"2018-10-16",{"date":73,"type":61},"2029-12-01",{"name":5,"class":6},1]